Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...

Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show superior outcomes to existing drugs. CagriSema, which includes a nascent ...

Novo Nordisk A/S' CagriSema disappointed investors again, but today's update should not have surprised anyone. The flexible dosing protocol in the REDEFINE trials likely led to suboptimal efficacy ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

of CagriSema in overweight or obese patients without type 2 diabetes. Headquarters of pharmaceutical company Novo Nordisk in Copenhagen, Denmark, on Sept. 26, 2023. (Tom Little/File photo ...

Over 68 weeks, CagriSema produced an average 15.7% weight ... December study results from Novo Nordisk revealed that the medication only achieved about 20% weight reduction aim, failing the ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...